Document is current
Any future updates will be listed below
-
Authors
Haviv, Doron
Remšík, Ján https://orcid.org/0000-0002-3228-2896
Gatie, Mohamed https://orcid.org/0000-0001-8500-5609
Snopkowski, Catherine
Takizawa, Meril
Pereira, Nathan
Bashkin, John
Jovanovich, Stevan https://orcid.org/0000-0002-3285-1091
Nawy, Tal https://orcid.org/0000-0003-3720-3699
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Boire, Adrienne
Hadjantonakis, Anna-Katerina
Pe’er, Dana https://orcid.org/0000-0002-9259-8817
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA209975)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (DK127821)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA233284)
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 28 February 2024
First Online: 2 April 2024
Competing interests
: D.P. is a member of the scientific advisory board of and has equity in Insitro. A.B. holds an unpaid position on the scientific advisory board of Evren Scientific and is an inventor on patents 62/258,044, 10/413,522 and 63/052,139 filed by Memorial Sloan Kettering Cancer Center. A.B. and J.R. are inventors of provisional patent applications 63/449,817 and 63/449,823 filed by Memorial Sloan Kettering Cancer Center. J.B., S.J. and N.P. were employees of S2 Genomics during this work and own company stock. The other authors declare no competing interests.
